Fluidigm Corporation Launches Low-Cost Assays for Gene Expression, SNP Genotyping and Target-Specific Primers for Next-Generation Sequencing

Fluidigm Corporation (NASDAQ:FLDM) today announced the availability of assays and primers optimized for the company’s integrated fluidic circuit technology. Fluidigm Assays and Target-specific Primers will provide customers with significantly lower costs than today’s standard solutions, at volumes appropriate for microfluidics, and flexible chemistries so that customers can easily create highly multiplexed panels using off-the-shelf and custom content focused on their particular research area. As part of the program, Fluidigm will provide the assay primer locus sequences with every order.